tradingkey.logo
tradingkey.logo
検索

Biontech SE

BNTX
ウォッチリストに追加
91.220USD
0.0000.00%
終値 06/26, 16:00ET15分遅れの株価
23.07B時価総額
損失額直近12ヶ月PER

詳細情報 Biontech SE 企業名

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Biontech SEの企業情報

企業コードBNTX
会社名Biontech SE
上場日Oct 10, 2019
最高経営責任者「CEO」Sahin (Ugur)
従業員数6772
証券種類Depository Receipt
決算期末Oct 10
本社所在地An der Goldgrube 12
都市MAINZ
証券取引所NASDAQ OMX - NASDAQ BASIC
Germany
郵便番号55131
電話番号4949613190840
ウェブサイトhttps://www.biontech.com/
企業コードBNTX
上場日Oct 10, 2019
最高経営責任者「CEO」Sahin (Ugur)

Biontech SEの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
692.54K
-10.83%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
1.43K
+44.60%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mr. Michael Motschmann
Mr. Michael Motschmann
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Michael Horowicz
Mr. Michael Horowicz
Director, Investor Relations
Director, Investor Relations
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
692.54K
-10.83%
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
1.43K
+44.60%
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Prof. Ugur Sahin, M.D.
Prof. Ugur Sahin, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--

よくある質問

Biontech SEの上位5名の株主は誰ですか?

Biontech SEの上位5名の株主は以下のとおりです。Dr. Sierk Poetting, Ph.D.

Biontech SE(BNTX)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Biontech SEの株式を保有している機関は802社あり、保有株式の総市場価値は約51.86Mで、全体の20.51%を占めています。2025Q4と比較して、機関の持ち株は-1292358.00増加しています。

Biontech SEの最大の収益源は何ですか?

2026Q1において、Collaboration Revenue部門がBiontech SEにとって最大の収益を生み出しており、その金額は84.43Mで、全収益の77.75%を占めています。
KeyAI